Compare GRPN & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRPN | RIGL |
|---|---|---|
| Founded | 2008 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 911.8M |
| IPO Year | 2011 | 2000 |
| Metric | GRPN | RIGL |
|---|---|---|
| Price | $12.20 | $45.75 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | $25.33 | ★ $64.40 |
| AVG Volume (30 Days) | ★ 1.2M | 221.2K |
| Earning Date | 11-09-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1867.68 |
| EPS | N/A | ★ 1.97 |
| Revenue | ★ $2,843,877,000.00 | $294,282,000.00 |
| Revenue This Year | $1.72 | $3.77 |
| Revenue Next Year | $7.23 | $19.69 |
| P/E Ratio | ★ N/A | $22.55 |
| Revenue Growth | N/A | ★ 64.15 |
| 52 Week Low | $9.17 | $24.84 |
| 52 Week High | $29.90 | $52.61 |
| Indicator | GRPN | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 30.53 | 47.05 |
| Support Level | $11.86 | $44.83 |
| Resistance Level | $13.80 | $51.00 |
| Average True Range (ATR) | 1.09 | 2.54 |
| MACD | -0.31 | -0.63 |
| Stochastic Oscillator | 8.86 | 54.72 |
Groupon Inc is a globalised, scaled two-sided marketplace that connects consumers to merchants. Its categories include Local: local inventory includes things to do, beauty and wellness, food and drink, home and automotive services, online services, as well as other types of experiences and services. Goods: Includes merchandise across multiple product lines, such as electronics, sporting goods, jewelry, toys, household items and apparel, and Travel: Features travel experiences at both discounted and market rates, including hotels, airfare, and package deals covering both domestic and international travel. The company operates in two segments, North America and International, with the majority of revenue from the Local category from the North America Segment.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.